Olink Proteomics

Enabling precision medicine

Company details

Year Aquired

2019

Location

Uppsala, Sweden

Revenue

472

Sector

Life Science

Employees

127

Investment Themes

Changing Demographics

Contact

If you want to know more about Olink Proteomics please contact Tommi Unkuri at: tommi.unkuri@summaequity.com

Olink at a glance

Olink develops and markets its unique technology for protein analysis in human protein biomarker research. Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchers to analyze large numbers of proteins with high-throughput analysis, exceptional data quality, and minimal sample consumption. This makes research possible, which previously could not be done, at lower unit costs. The technology drives precision medicine by improving the understanding of the interaction of proteins and human disease, which is key to improving treatment and patient outcomes across many disease areas.

 

Key developments in 2020

In June 2020, Olink launched Explore, a new offering where its PEA technology is applied on Next-Generation Sequencing platforms, enabling greater significantly improved scale and higher throughput than ever before. This offering further strengthens Olink’s market position in high plex proteomics and enables its customers to continue making great leaps in understanding of real-time human biology.

Despite Covid-19, Olink has driven a ramp-up of the organization, increasing headcount by 60% and expect to continue its growth journey over the coming years. While Covid-19 adversely impacted the revenue growth for 2020 as customers had issues accessing their labs, Olink has continued to build a very strong pipeline and positive momentum in the market.

Impact Dimensions

The challenges we face

We currently suffer from ineffective medication due to a lack of understanding of the biology of diseases. The shift from "one size fits all" approach to precision medicine is a colossal challenge for science. Delivering the right treatment, to the right patient at the appropriate time requires developing protein biomarker panels to improve our understanding of the human biology and optimize the development of new drugs and treatments.

 

%
of patients receive no benefit from treatment with the top 10 best-selling drugs in the world
%
Share of GDP spent on healthcare in the OECD

 

What is the outcome?

Olink contributes to the understanding of the human biology through its unique technology aimed at science related to proteomics. Olink’s approach enables science that was not previously possible, and is a key contributor to precision medicine.

 

Who are the stakeholders?

Olink's customers are primarily found in pharma and in academic centers, who are focused on drug discovery and understanding biology in human disease. Olink's technology can enable these customers to drive the future of precision medicine, which will greatly benefit individual patients and health systems.

 

How big is the effect, and does it last?

Olink, with a library of over 1 536 validated protein targets, has been mentioned in 530+ publications, supporting protein biomarker discovery research globally. The company has hundreds of customers worldwide. Enabling precision medicine is important to drive better patient outcomes and sustainable costs in healthcare systems over time.

 

If Olink didn’t exist…

Since Olink provides a truly unique technology to the market, it makes a great contribution to precision medicine. If Olink did not exist, a vast majority of the research that it enables would not get done.

 

Impact risk: what can go wrong?

Product quality is fundamentally important, so if Olink would be unable to deliver strong product quality, its customers would likely stop using its products.

Year Aquired

2019

Revenue

472

Employees

127

Investment Themes

Changing Demographics

Sector

Life Science

Location

Uppsala, Sweden

Contact

If you want to know more about Olink Proteomics please contact Tommi Unkuri at: tommi.unkuri@summaequity.com

Website

Video

SDG Alignment
SDG Wheel
SDG 3
KPI reporting
SDG 8

REVENUE (SEKm)

2020
+17%
472
2019
404
2018
298
SDG 3

NO. OF PROTEIN DATA POINTS GENERATED

2020
+65%
250 m
2019
151 m
2018
88 m

NUMBER OF PUBLICATIONS

2020
+45%
500+
2019
343
2018
221
SDG 3

NO. OF MANUFACTURED KITS

2019
+61%
21,9k
2018
13.6k

Learn more about Olink

Olink Proteomics AB announce acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays

Dear Friends, UPPSALA, Sweden, May 12, 2020 – Olink today announced the acquisition of Agrisera AB, a Swedish company specializing in polyclonal and monoclonal antibody production. Agrisera offers an extensive collection of primary and secondary antibodies for a broad range of applications, available in various quantities. The acquisition is an important milestone for Olink in its…

Read the story

Summa Equity acquires Olink Proteomics

Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide. Summa Equity is excited to support this development, and to…

Read the story

Olink Proteomics AB announce acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays

Dear Friends, UPPSALA, Sweden, May 12, 2020 – Olink today announced the acquisition of Agrisera AB, a Swedish company specializing in polyclonal and monoclonal antibody production. Agrisera offers an extensive collection of primary and secondary antibodies for a broad range of applications, available in various quantities. The acquisition is an important milestone for Olink in its...
Learn more

Summa Equity acquires Olink Proteomics

Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide. Summa Equity is excited to support this development, and to...
Learn more